Taipei, July 17, 2025 ––ImmunAdd Inc. is pleased to announce its participation in BIO Asia–Taiwan 2025, taking place from July 24 to July 27 at TaiNEX 2 (Taipei Nangang Exhibition Center Hall 2). During the exhibition, ImmunAdd will present key achievements from its next-generation vaccine adjuvant platform and engage with domestic and international partners across […]
TAIPEI, Taiwan May 15, 2025 – Japan Patent Office has granted ImmunAdd the patent on saponin conjugate and vaccine or pharmaceutical composition comprising the same. “Innovation for Better Health” We are ImmunAdd.
TAIPEI, Taiwan May 12, 2025 – U.S. Patent and Trademark Office has granted ImmunAdd the patent on saponin conjugate and vaccine or pharmaceutical composition comprising the same. “Innovation for Better Health” We are ImmunAdd.
TAIPEI, Taiwan Mar. 5, 2025 – Korean Intellectual Property Office has granted ImmunAdd the patent on saponin conjugate and vaccine or pharmaceutical composition comprising the same. “Innovation for Better Health” We are ImmunAdd.
TAIPEI, Taiwan Oct. 23, 2024 – The Israel Patent Office has granted ImmunAdd the patent on saponin conjugate and vaccine or pharmaceutical composition comprising the same. “Innovation for Better Health” We are ImmunAdd.
TAIPEI, Taiwan Oct. 23, 2024 – China National Intellectual Property Administration has granted ImmunAdd the patent on saponin conjugate and vaccine or pharmaceutical composition comprising the same. “Innovation for Better Health” We are ImmunAdd.
TAIPEI, Taiwan Jul. 10, 2024 – ImmunAdd won the Startup of the Year at the 2024 Taiwan BIO Awards and the Awards ceremony will be held on July 25th. ImmunAdd is a biotech pharmaceutical research and development company focused on drug design and formulation development. ImmunAdd was founded in 2022 but has put efforts into […]
TAIPEI, Taiwan Jul 5, 2024 – Taiwan Intellectual Property Office has granted ImmunAdd the patent on the preparation of triterpenoid compound. “Innovation for Better Health” We are ImmunAdd.
TAIPEI, Taiwan May 16, 2024 – ImmunAdd, a privately held company developing a fully synthetic saponin-based small molecule, proudly announced that our funder and CEO, Dr. Pi-Hui Liang, awarded “Outstanding Research Award”. Dr. Pi-Hui Liang leads her team, leaning on their erudite knowledge in medical chemistry, drug formulation, and regulations, to work on developing therapies […]
TAIPEI, Taiwan Jan 18, 2024 – IP Australia has granted ImmunAdd the patent on the synthetic saponin molecules. Innovation for Better Health We are ImmunAdd.
- 1
- 2